ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Schizophrenia Treatment Trial Meets Primary Endpoint americanpharmaceuticalreview
September 21, 2020Boehringer Ingelheim announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint. The data showed improvement in cognition in stable adult patients with schizophrenia.
Pharma Sources Insight July 2025
